FDA Launches Review of 7 Risky Peptides Backed by RFK Jr. and MAHA Allies
The FDA is preparing to reconsider restrictions on controversial peptide drugs, but the push is colliding with safety concerns and political pressure.
According to the Associated Press, federal regulators will meet in July to review whether seven peptides, previously restricted over safety risks, should be allowed back into wider use through compounding pharmacies.
The move follows repeated calls from Health Secretary Robert F. Kennedy Jr., who has promoted peptides as part of his “Make America Healthy Again” agenda and said he has personally used them.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →
These drugs, often marketed for muscle growth, recovery, and anti-aging, have little clinical evidence and were flagged by the FDA in 2023 for potential toxicity and lack of human testing.
Critics warn the shift could weaken the FDA’s drug approval system, while supporters argue it could bring a booming gray market under medical oversight.
The July panel does not finalize policy, but it could trigger one of the most significant reversals in U.S. drug regulation in years.
Download a FREE Pocket Constitution NOW →
